Review Article
Hepatitis B: Model Systems and Therapeutic Approaches
Table 1
Cell models of HBV infection.
| | System | Cell source | HBV genome background | Advantage | Limitation | Application | Reference |
| | HepG2.2.15 | HepG2/transfected | pDolTHBV-1 plasmid vector containing two head-to-tail copies of HBV genome | Stable express HBV particles | Limited HBV production | Evaluate the effects of conventional antiviral medications
Investigate HBV-associated HCC
Investigate inflammatory factors | [13, 14] |
| | HepAD38 | HepG2/transfected | 0.3 μg pUHD15-1neo and 2.7 μg ptetHBV (single pgRNA) | Support formation of
cccDNA
High-level production | — | Screen HBV replication inhibitors Support immune-related studies | [15] |
| | HepG2-NTCP | HepG2/infection | — | Support infection
High level of HBV | Only partially mimic normal hepatocytes
No spread of HBV | Support screening of antiviral medications
Molecule-associated HBV entry | [16] |
| | HepRG | HepRG/infection | — | Mimic normal hepatocytes DMSO restriction | Long differentiated time | — | [17] |
| | Hepatocyte-like cells | Human pluripotent stem cells Human embryonic stem cells/infection | — | Quantity production
Support entire life cycle
Naturally express NTCP
Spread of HBV | Low replication efficiency | Support high-throughput screening of antiviral medications Screen personalized antiviral medications | [18] |
| | Primary human hepatocytes | Primary human hepatocytes/infection | — | Mimic normal hepatocytes the best | Expensive, scarce, limited life span | Screen antiviral molecule and related mechanisms Investigate interactions between virus and host hepatocytes | [19–21] |
|
|
cccDNA, covalently closed circular DNA.
|
